Linked Life Data

12765945

Source:http://linkedlifedata.com/resource/pubmed/id/12765945

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12765945rdf:typepubmed:Citationlld:pubmed
pubmed-article:12765945lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:12765945lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:12765945lifeskim:mentionsumls-concept:C0011860lld:lifeskim
pubmed-article:12765945lifeskim:mentionsumls-concept:C0015677lld:lifeskim
pubmed-article:12765945lifeskim:mentionsumls-concept:C0205054lld:lifeskim
pubmed-article:12765945lifeskim:mentionsumls-concept:C0071097lld:lifeskim
pubmed-article:12765945lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:12765945lifeskim:mentionsumls-concept:C0599781lld:lifeskim
pubmed-article:12765945lifeskim:mentionsumls-concept:C1550605lld:lifeskim
pubmed-article:12765945lifeskim:mentionsumls-concept:C0456205lld:lifeskim
pubmed-article:12765945pubmed:issue6lld:pubmed
pubmed-article:12765945pubmed:dateCreated2003-5-26lld:pubmed
pubmed-article:12765945pubmed:abstractTextThe effect of pioglitazone on splanchnic glucose uptake (SGU), endogenous glucose production (EGP), and hepatic fat content was studied in 14 type 2 diabetic patients (age 50 +/- 2 years, BMI 29.4 +/- 1.1 kg/m(2), HbA(1c) 7.8 +/- 0.4%). Hepatic fat content (magnetic resonance spectroscopy) and SGU (oral glucose load- insulin clamp technique) were quantitated before and after pioglitazone (45 mg/day) therapy for 16 weeks. Subjects received a 7-h euglycemic insulin (100 mU. m(-2). min(-1)) clamp, and a 75-g oral glucose load was ingested 3 h after starting the insulin clamp. Following glucose ingestion, the steady-state glucose infusion rate during the insulin clamp was decreased appropriately to maintain euglycemia. SGU was calculated by subtracting the integrated decrease in glucose infusion rate during the 4 h after glucose ingestion from the ingested glucose load. 3-[(3)H]glucose was infused during the initial 3 h of the insulin clamp to determine rates of EGP and glucose disappearance (R(d)). Pioglitazone reduced fasting plasma glucose (10.0 +/- 0.7 to 7.5 +/- 0.6 mmol/l, P < 0.001) and HbA(1c) (7.8 +/- 0.4 to 6.7 +/- 0.3%, P < 0.001) despite increased body weight (83 +/- 3 to 86 +/- 3 kg, P < 0.001). During the 3-h insulin clamp period before glucose ingestion, pioglitazone improved R(d) (6.9 +/- 0.5 vs. 5.2 +/- 0.5 mg. kg(-1). min(- 1), P < 0.001) and insulin-mediated suppression of EGP (0.21 +/- 0.04 to 0.06 +/- 0.02 mg. kg(-1). min(-1), P < 0.01). Following pioglitazone treatment, hepatic fat content decreased from 19.6 +/- 3.6 to 10.4 +/- 2.1%, (P < 0.005), and SGU increased from 33.0 +/- 2.8 to 46.2 +/- 5.1% (P < 0.005). Pioglitazone treatment in type 2 diabetes 1) decreases hepatic fat content and improves insulin-mediated suppression of EGP and 2) augments splanchnic and peripheral tissue glucose uptake. Improved splanchnic/peripheral glucose uptake and enhanced suppression of EGP contribute to the improvement in glycemic control in patients with type 2 diabetes.lld:pubmed
pubmed-article:12765945pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12765945pubmed:languageenglld:pubmed
pubmed-article:12765945pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12765945pubmed:citationSubsetAIMlld:pubmed
pubmed-article:12765945pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12765945pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12765945pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12765945pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12765945pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12765945pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12765945pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12765945pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12765945pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12765945pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12765945pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12765945pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12765945pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12765945pubmed:statusMEDLINElld:pubmed
pubmed-article:12765945pubmed:monthJunlld:pubmed
pubmed-article:12765945pubmed:issn0012-1797lld:pubmed
pubmed-article:12765945pubmed:authorpubmed-author:Pratipanawatr...lld:pubmed
pubmed-article:12765945pubmed:authorpubmed-author:Pratipanawatr...lld:pubmed
pubmed-article:12765945pubmed:authorpubmed-author:DeFronzoRalph...lld:pubmed
pubmed-article:12765945pubmed:authorpubmed-author:MiyazakiYoshi...lld:pubmed
pubmed-article:12765945pubmed:authorpubmed-author:BajajMandeepMlld:pubmed
pubmed-article:12765945pubmed:authorpubmed-author:GlassLeonardLlld:pubmed
pubmed-article:12765945pubmed:authorpubmed-author:CersosimoEuge...lld:pubmed
pubmed-article:12765945pubmed:authorpubmed-author:SuraamornkulS...lld:pubmed
pubmed-article:12765945pubmed:authorpubmed-author:HardiesLou...lld:pubmed
pubmed-article:12765945pubmed:issnTypePrintlld:pubmed
pubmed-article:12765945pubmed:volume52lld:pubmed
pubmed-article:12765945pubmed:ownerNLMlld:pubmed
pubmed-article:12765945pubmed:authorsCompleteYlld:pubmed
pubmed-article:12765945pubmed:pagination1364-70lld:pubmed
pubmed-article:12765945pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:meshHeadingpubmed-meshheading:12765945...lld:pubmed
pubmed-article:12765945pubmed:year2003lld:pubmed
pubmed-article:12765945pubmed:articleTitlePioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.lld:pubmed
pubmed-article:12765945pubmed:affiliationDiabetes Division, Department of Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284-7886, USA. mandeepbajaj@hotmail.comlld:pubmed
pubmed-article:12765945pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12765945pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:12765945pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:12765945pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12765945lld:pubmed
More...